Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma [ACC]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.

Start Date18 Dec 2030

Sponsor / Collaborator

Actuate Therapeutics, Inc.Startup

NCT05077800 / RecruitingPhase 2IIT

A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor 9-ING-41 and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Cancer

The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease.
The names of the study drugs involved in this study are:
* 9-ING-41
* Losartan
* Ferumoxytol
* FOLFIRINOX (made up of 4 different drugs):
* 5-Fluorouracil (5-FU)
* Oxaliplatin
* Irinotecan
* Leucovorin

Start Date21 Mar 2022

Sponsor / Collaborator

Actuate Therapeutics, Inc.Startup

[+1]

NCT05116800 / WithdrawnPhase 2IIT

A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma. 9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.

Start Date01 Mar 2022

Sponsor / Collaborator

Brown University

[+1]

100 Clinical Results associated with Elraglusib

100 Translational Medicine associated with Elraglusib

100 Patents (Medical) associated with Elraglusib

Literatures (Medical) associated with Elraglusib

01 Jun 2024·JHEP Reports

Glycogen synthase kinase 3 activity enhances liver inflammation in MASH

Article

Author: Islam, Shahidul ; Kim, Iljung ; Pavelko, Kevin D ; Mazar, Andrew P ; Li, Hu ; Warasnhe, Khaled ; Bamidele, Adebowale O ; Noh, Yung-Kyun ; Ibrahim, Samar H ; Kim Lee, Hyun Se ; Holmes, Heather ; Furuta, Kunimaro ; Valenzuela-Pérez, Lucía ; Guo, Qianqian ; Romero, Michael F ; Khoury, Mireille ; Correia, Cristina ; Sussman, Caroline R ; Meroueh, Chady ; Hirsova, Petra

Background & Aims:

Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by excessive circulating toxic lipids, hepatic steatosis, and liver inflammation. Monocyte adhesion to liver sinusoidal endothelial cells (LSECs) and transendothelial migration (TEM) are crucial in the inflammatory process. Under lipotoxic stress, LSECs develop a proinflammatory phenotype known as endotheliopathy. However, mediators of endotheliopathy remain unclear.

Methods:

Primary mouse LSECs isolated from C57BL/6J mice fed chow or MASH-inducing diets rich in fat, fructose, and cholesterol (FFC) were subjected to multi-omics profiling. Mice with established MASH resulting from a choline-deficient high-fat diet (CDHFD) or FFC diet were also treated with two structurally distinct GSK3 inhibitors (LY2090314 and elraglusib [9-ING-41]).

Results:

Integrated pathway analysis of the mouse LSEC proteome and transcriptome indicated that leukocyte TEM and focal adhesion were the major pathways altered in MASH. Kinome profiling of the LSEC phosphoproteome identified glycogen synthase kinase (GSK)-3β as the major kinase hub in MASH. GSK3β-activating phosphorylation was increased in primary human LSECs treated with the toxic lipid palmitate and in human MASH. Palmitate upregulated the expression of C-X-C motif chemokine ligand 2, intracellular adhesion molecule 1, and phosphorylated focal adhesion kinase, via a GSK3-dependent mechanism. Congruently, the adhesive and transendothelial migratory capacities of primary human neutrophils and THP-1 monocytes through the LSEC monolayer under lipotoxic stress were reduced by GSK3 inhibition. Treatment with the GSK3 inhibitors LY2090314 and elraglusib ameliorated liver inflammation, injury, and fibrosis in FFC- and CDHFD-fed mice, respectively. Immunophenotyping using cytometry by mass cytometry by time of flight of intrahepatic leukocytes from CDHFD-fed mice treated with elraglusib showed reduced infiltration of proinflammatory monocyte-derived macrophages and monocyte-derived dendritic cells.

Conclusion:

GSK3 inhibition attenuates lipotoxicity-induced LSEC endotheliopathy and could serve as a potential therapeutic strategy for treating human MASH.

Impact and Implications:

LSECs under lipotoxic stress in MASH develop a proinflammatory phenotype known as endotheliopathy, with obscure mediators and functional outcomes. The current study identified GSK3 as the major driver of LSEC endotheliopathy, examined its pathogenic role in myeloid cell-associated liver inflammation, and defined the therapeutic efficacy of pharmacological GSK3 inhibitors in murine MASH. This study provides preclinical data for the future investigation of GSK3 pharmacological inhibitors in human MASH. The results of this study are important to hepatologists, vascular biologists, and investigators studying the mechanisms of inflammatory liver disease and MASH, as well as those interested in drug development.

01 Feb 2024·Clinical cancer research : an official journal of the American Association for Cancer Research

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Article

Author: Cervantes, Andrés ; Cavalcante, Ludimila ; Munster, Pamela ; Harvey, R. Donald ; Borden, Brittany A. ; Powell, Steven ; Longstreth, James ; Coveler, Andrew L. ; Mikrut, William ; Mazar, Andrew P. ; Giles, Francis J. ; Kurzrock, Razelle ; Weisskittel, Taylor ; Li, Hu ; Koukol, Austin ; Smith, Sheri ; Sahai, Vaibhav ; Bastos, Bruno ; Steeghs, Neeltje ; Ma, Wen Wee ; Carneiro, Benedito A. ; Safran, Howard ; Davis, Elizabeth ; Mahalingam, Devalingam ; Saeed, Anwaar ; Sahebjam, Solmaz

Abstract:

Purpose::

The safety, pharmacokinetics, and efficacy of elraglusib, a glycogen synthase kinase-3β (GSK-3β) small-molecule inhibitor, as monotherapy or combined with chemotherapy, in patients with relapsed or refractory solid tumors or hematologic malignancies was studied.

Patients and Methods::

Elraglusib (intravenously twice weekly in 3-week cycles) monotherapy dose escalation was followed by dose escalation with eight chemotherapy regimens (gemcitabine, doxorubicin, lomustine, carboplatin, irinotecan, gemcitabine/nab-paclitaxel, paclitaxel/carboplatin, and pemetrexed/carboplatin) in patients previously exposed to the same chemotherapy.

Results::

Patients received monotherapy (n = 67) or combination therapy (n = 171) elraglusib doses 1 to 15 mg/kg twice weekly. The initial recommended phase II dose (RP2D) of elraglusib was 15 mg/kg twice weekly and was defined, without dose-limiting toxicity observation, due to fluid volumes necessary for drug administration. The RP2D was subsequently reduced to 9.3 mg/kg once weekly to reduce elraglusib-associated central/peripheral vascular access catheter blockages. Other common elraglusib-related adverse events (AE) included transient visual changes and fatigue. Grade ≥3 treatment-emergent AEs occurred in 55.2% and 71.3% of patients on monotherapy and combination therapy, respectively. Part 1 monotherapy (n = 62) and part 2 combination (n = 138) patients were evaluable for response. In part 1, a patient with melanoma had a complete response, and a patient with acute T-cell leukemia/lymphoma had a partial response (PR). In part 2, seven PRs were observed, and the median progression-free survival and overall survival were 2.1 [95% confidence interval (CI), 2–2.6] and 6.9 (95% CI, 5.7–8.4) months, respectively.

Conclusions::

Elraglusib had a favorable toxicity profile as monotherapy and combined with chemotherapy and was associated with clinical benefit supporting further clinical evaluation in combination with chemotherapy.

31 Dec 2022·Cancer biology & therapy

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

Article

Author: Cavalcante, Ludimila ; Safran, Howard ; Zhou, Lanlan ; El-Deiry, Wafik S. ; Giles, Francis J. ; Carneiro, Benedito A. ; Treaba, Diana O. ; Hsu, Andrew ; Makwana, Nirav P. ; Huntington, Kelsey E. ; Olszewski, Adam J. ; De Souza, Andre

GSK-3β is a serine/threonine kinase implicated in tumorigenesis and chemotherapy resistance. GSK-3β blockade downregulates the NF-κB pathway, modulates immune cell PD-1 and tumor cell PD-L1 expression, and increases CD8 + T cell and NK cell function. We report a case of adult T-cell leukemia/lymphoma (ATLL) treated with 9-ING-41, a selective GSK-3β inhibitor in clinical development, who achieved a durable response. A 43-year-old male developed diffuse lymphadenopathy, and biopsy of axillary lymph node showed acute-type ATLL. Peripheral blood flow cytometry revealed a circulating clonal T cell population, and CSF was positive for ATLL involvement. After disease progression on the 3^rd line of treatment, he started treatment with 9-ING-41 monotherapy in a clinical trial (NCT03678883). CT imaging after seven months showed a partial response. Sustained reduction of peripheral blood ATLL cells lasted 15 months. Treatment of patient-derived CD8 + T cells with 9-ING-41 increased the secretion of IFN-γ, granzyme B, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In conclusion, treatment of a patient with refractory ATLL with the GSK-3β inhibitor 9-ING-41 resulted in a prolonged response. Ongoing experiments are investigating the hypothesis that 9-ING-41-induced T cell activation and immunomodulation contributes to its clinical activity. Further clinical investigation of 9-ING-41 for treatment of ATLL is warranted.

News (Medical) associated with Elraglusib

17 Dec 2024

·pipelinereview.com

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

CHICAGO, IL and FORT WORTH, TX, USA I December 17, 2024 I Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced new positive data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (Actuate-1801 Part 3B). A pre-specified analysis was triggered by reaching >70% death events in the GnP control arm (data cut off November 15, 2024). The analysis of interim data demonstrated treatment with elraglusib in combination with GnP resulted in statistically significant increases in 1-year survival rate (p value of 0.002) and median overall survival (p value of 0.016, hazard ratio of 0.63) versus treatment with GnP alone. The combination treatment also resulted in increased Objective Response Rates (ORR) and Disease Control Rates (DCR) in the elraglusib/GnP combination arm versus the GnP control arm. “These interim results are highly encouraging and underscore the transformative potential of elraglusib in the treatment of metastatic pancreatic cancer,” said Daniel Schmitt, President & Chief Executive Officer of Actuate. “The improvement in median and overall long-term survival, disease control rate and overall response rate compared to GnP alone, combined with elraglusib’s favorable risk-benefit profile, offers the possibility of improved outcomes for patients with limited treatment alternatives. We are excited to continue evaluating the potential of elraglusib, a novel immune-oncology GSK-3 targeted approach for mPDAC, and look forward to engaging with the FDA in 1H 2025 to share topline data and discuss next steps, including a proposed phase 3 registration trial.” Inhibition of GSK-3β may inhibit tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, activation of innate anti-tumor immunity and regulation of gene expression, leading to alterations in tumor metabolism and Epithelial-to-Mesenchymal Transition (EMT). Study highlights include: “Pancreatic cancer is one of the most aggressive and lethal cancers with less than 5% survival rate in the US at 5 years. We are encouraged by consistent evidence of significant clinical benefit and anti-tumor activity in the elraglusib combination arm across multiple endpoints in this study,” said Dr. Andrew Mazar, Actuate’s Scientific Co-Founder and Chief Operating Officer. “Further, the favorable risk-benefit profile observed to date may provide a treatment option for many patients with metastatic pancreatic cancer that may not tolerate more aggressive and less tolerable chemotherapy approaches.” The ongoing Actuate-1801 Part 3B study (NCT04239092) is a randomized, controlled Phase 2 trial of elraglusib with GnP versus GnP alone in first line mPDAC. The trial enrolled 286 mPDAC patients with no prior systemic treatment for metastatic disease, who were randomized 2:1 to the elraglusib treatment arm (elraglusib + GnP) or the control arm (GnP alone). Elraglusib is administered at a dose of 9.3 mg/kg by IV infusion on Day 1 of each week of a 28-day cycle. The primary endpoint is 1-year survival rate, with mOS the primary parameter for summarization of survival data at the end of the study. Secondary endpoints are DCR, ORR, PFS and AE. About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DNA Damage Response (DDR) pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com. SOURCE : Actuate Therapeutics

Clinical ResultPhase 2Phase 3Immunotherapy

17 Dec 2024

·endpts.com

Affimed’s early lung cancer data disappoint; Indapta's $22M round

Plus, news about Akamis Bio, Tenaya Therapeutics, Reviva, Actuate Therapeutics, CG Oncology and Candel Therapeutics: Affimed shares early lung cancer data: In a Phase 1/2a trial, its bispecific innate cell engager, called AFM24, plus Roche’s Tecentriq reached a 21% overall response rate in 33 people with pretreated EGFR wild-type non-small cell lung cancer. The ORR was 24% in 17 EGFR-mutant patients. Affimed said it has selected the 720 mg dose for further development. Affimed’s shares $AFMD were down about 22% on Tuesday morning after it announced the data. — Ayisha Sharma Indapta Therapeutics gets $22.5M: The Houston and Seattle biotech raised the new round to fund clinical development of its allogeneic natural killer cell therapy. The biotech emerged with a $50 million Series A in February 2022. — Kyle LaHucik Oncolytic virus biotech has new funding and a deal in China: Akamis Bio announced that it raised new funding plus inked an out-licensing deal with Xuanzhu Biopharma for its lead candidate for up to $60 million. That figure includes private funding, the upfront for the outlicensing deal and biobucks, though CEO Howard Davis declined to disclose how much each portion is. Akamis, which rebranded from PsiOxus in 2023, is developing a gene therapy called NG-350A that is designed to target tumor cells and drive expression of CD40 agonist antibodies. The hope is that by engaging these key immune proteins, the therapy can trigger the immune system to attack the cancer. The company plans to use the funds to study the therapy in a Phase 1b rectal cancer trial. — Lei Lei Wu Tenaya’s shares slide: The company reported early results for an AAV therapy for three patients with a genetic heart condition called MYBPC3-associated hypertrophic cardiomyopathy. It pointed to biomarkers that suggested the therapy was having an initial effect, though it said “longer-term data are needed to characterize TN-201’s activity.” Tenaya said longer follow-up data as well as results from a higher dose cohort are expected next year. The company’s shares $TNYA fell 47% on Tuesday morning. — Lei Lei Wu Reviva’s long-term results for its schizophrenia drug: The Cupertino, CA-based biotech said brilaroxazine administered once daily showed sustained efficacy over one year in the open-label extension portion of a Phase 3 trial. There were no side effects with an incidence of more than 5%, but there was a 35% treatment discontinuation rate. Its stock $RVPH fell about 44% in trading on Tuesday morning. — Ayisha Sharma Actuate’s pancreatic cancer asset boosts survival: The drugmaker’s elraglusib in combination with gemcitabine and nab-paclitaxel (GnP) almost doubled the one-year survival rate versus GnP alone in a Phase 2 trial, good for a p-value of 0.002. Actuate said that 38% of treated patients were still alive at the cutoff date in November, compared with 19% of the control cohort. The company’s share price $ACTU was up 14% at market open on Tuesday. — Ayisha Sharma CG Oncology raised $238 million in its public offering, up from the $204 million it planned to bring in. — Jaimy Lee Candel ended up raising $92 million in its public offering. — Jaimy Lee

Clinical ResultPhase 3Phase 1Gene TherapyCell Therapy

26 Nov 2024

·www.globenewswire.com

Actuate Therapeutics to be Added to Russell 2000® Index

CHICAGO and FORT WORTH, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers announced today that the Company will be added to the Russell 2000® Index as part of the planned fourth quarter IPO additions effective after the U.S market opens on December 23, 2024. The Russell 2000® Index measures the performance of the small-cap segment of the US equity market. The Russell 2000® Index is a subset of the Russell 3000® Index representing approximately 10% of the total market capitalization of that index. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership. Initial public offerings (IPOs) are added to the Russell US indexes on a quarterly basis. For more information on the Russell 2000® Index and the Preliminary List of IPO Additions: Russell US Index IPO additions and reports | LSEG About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DDR pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com. Forward-Looking Statements This press release contains forward-looking statements about us, including our clinical trials, development plans, industry, and our planned addition of the Russell 2000® Index. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to the potential benefits of and continued inclusion of the Company in the Russell 2000® Index, that clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve favorable results in clinical trials or preclinical studies or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; and our ability to fund development activities. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on November 13, 2024 and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. Investor Contact Mike Moyer Managing Director LifeSci Advisors, LLC mmoyer@lifesciadvisors.com

ImmunotherapyIPO

100 Deals associated with Elraglusib

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16047

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic melanoma	Phase 2	US	Actuate Therapeutics, Inc.Startup	31 May 2023
Metastatic melanoma	Phase 2	US	Lantern Pharma, Inc.	31 May 2023
Pancreatic adenocarcinoma metastatic	Phase 2	US	Actuate Therapeutics, Inc.Startup	21 Mar 2022
Secondary malignant neoplasm of pancreas	Phase 2	US	Actuate Therapeutics, Inc.Startup	21 Mar 2022
Ewing Sarcoma	Phase 2	US	Actuate Therapeutics, Inc.Startup	01 Mar 2022
Metastatic osteosarcoma	Phase 2	US	Actuate Therapeutics, Inc.Startup	01 Mar 2022
Advanced Pancreatic Adenocarcinoma	Phase 2	US	Actuate Therapeutics, Inc.Startup	26 Jan 2022
Advanced Pancreatic Adenocarcinoma	Phase 2	US	Incyte Corp.	26 Jan 2022
Pancreatic Ductal Adenocarcinoma	Phase 2	US	Actuate Therapeutics, Inc.Startup	26 Jan 2022
Pancreatic Ductal Adenocarcinoma	Phase 2	US	Incyte Corp.	26 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04239092 (Actuate-1801, GlobeNewswire) Manual	Phase 2	Pancreatic Cancer First line	286	Elraglusib + gemcitabine/nab-paclitaxel	fkjzlenkbm(jgjlrgxyoe) = mnoulfhgxn zdaaumfpgf (yhespjiheo ) Met View more	Positive	17 Dec 2024
NCT04239092 (Actuate-1801, GlobeNewswire) Manual	Phase 2	Pancreatic Cancer First line	286	gemcitabine/nab-paclitaxel	fkjzlenkbm(jgjlrgxyoe) = cbebemguvh zdaaumfpgf (yhespjiheo ) Met View more	Positive	17 Dec 2024
NCT03678883 (ASCO 12023 \| ASCO 22023) Manual	Phase 2	Advanced Pancreatic Ductal Adenocarcinoma	42	gemcitabine+Albumin-Bound Paclitaxel+Elraglusib	qynexydfcn(xflhttedzr) = cowoxeooix amitsoicnz (reewkdmwlo, 32.5 - 70.6) View more	Positive	26 May 2023
NCT03678883 (AACR2023) Manual	Phase 1/2	Advanced cancer Third line	-	elraglusib (melanoma)	iikuieinnm(ylicmikell) = jjrgrfceju klduvhaslr (qjmypiuywb )	Positive	14 Apr 2023
NCT03678883 (AACR2023) Manual	Phase 1/2	Advanced cancer Third line	-	elraglusib (colorectal cancer)	ksbhlztcwr(mbslrxuhup) = jreopkewpc bnpclnirxh (prsgwokeyu ) View more	Positive	14 Apr 2023
NCT04239092 (ASCO2022) Manual	Phase 1/2	Neoplasms	23	ElraglusibElraglusib alone or in combination with chemotherapy	qvhkzgcgio(ipvnxbcvdf) = none fwldrmyivm (ewlenuatpx ) View more	Positive	02 Jun 2022
NCT04239092 (ASCO2022) Manual	Phase 1/2	Neoplasms	23	Elraglusib + cyclophosphamide/topotecan or irinotecan		Positive	02 Jun 2022
NCT03678883 (Pubmed) Manual	Phase 1/2	Neoplasms \| Malignant glioma of brain	18	Lomustine+Elraglusib	weqpalvdun(nmsndkijgl) = mild vision changes 50%, infusion reactions 22% janurmjuia (umpwczpmvv ) View more	Positive	07 Feb 2022
NCT03678883 (ACTUATE 1801, SNO2021)	Phase 1/2	Glioma IDH \| 1p19q \| MGMT ... View more	18	9-ING-41 monotherapy	pycdvdwvzw(mmpbaymaqm) = hzsbgpizcn pecczpgphk (ycjvfxrrov ) View more	Positive	12 Nov 2021
NCT03678883 (ACTUATE 1801, SNO2021)	Phase 1/2	Glioma IDH \| 1p19q \| MGMT ... View more	18	9-ING-41 + Lomustine	khihirvsau(cxmqdnespj) = pjkvnfqcuq swphflmhup (frsoxwnuhr ) View more	Positive	12 Nov 2021
AACR2021	Not Applicable	Colorectal Cancer	-	9-ING-41	wlwhwvqvoo(vzlriuhdhe) = wwyeywxwgt zarwfyvujb (fuprkfdfdy ) View more	-	01 Jul 2021
NCT03678883 (ASCO 12021 \| ASCO 22021) Manual	Phase 1/2	Solid tumor \| Malignant glioma of brain \| Refractory Hematologic Malignancy	227	lomustine+9-ing-41	mybrepknso(evsesmoxpo) = gnadbkgnql acorfizcfa (tqbfxlmjya ) View more	Positive	28 May 2021
NCT03678883 (ASCO2020)	Phase 1	Neoplasms	101	9-ING-41 combined with chemotherapy	scppbokgaj(nstabzgksm) = n = 14 afldclcdqd (dvomeooaek ) View more	Positive	25 May 2020
NCT04218071 \| NCT03678883 \| NCT04239092 (Pubmed \| Anticancer Drugs)	Phase 1/2	Neuroblastoma	17	9-ING-41	yqsbfqbcgn(zroqimgqiq) = hdxdctuicz wanfidgzap (ckkmmunnez )	-	01 Sep 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis